Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy

被引:245
作者
Henson, Elizabeth S. [1 ]
Gibson, Spencer B. [1 ]
机构
[1] Univ Manitoba, Manitoba Inst Cell Biol, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada
关键词
tryosine kinase receptors; EGF; cancer; apoptosis; survival; AKT; MAPK; STAT; death receptors; mitochondria; caspase; transcription factors; Bcl-2 family members;
D O I
10.1016/j.cellsig.2006.05.015
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
There is a balance between cell death and survival in living organisms. The ability of cells to sense their environment and decide to survive or die is dependent largely upon growth factors. Epidermal growth factor (EGF) is a key growth factor regulating cell survival. Through its binding to cell surface receptors, EGF activates an extensive network of signal transduction pathways that include activation of the PI3K/AKT, RAS/ERK and JAK/STAT pathways. These pathways predominantly lead to activation or inhibition of transcription factors that regulate expression of both pro- and anti-apoptotic proteins effectively blocking the apoptotic pathway. In cancer, EGF signaling pathways are often dysfunctional and targeted therapies that block EGF signaling have been successful in treating cancers. In this review, we will discuss the EGF survival signaling network, how it cross-talks with the apoptotic signaling pathways and the therapeutic drugs targeting the EGF survival pathway used to treat cancers. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:2089 / 2097
页数:9
相关论文
共 95 条
[61]   ras oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells -: Epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation [J].
Liu, ZP ;
Li, HB ;
Derouet, M ;
Filmus, J ;
LaCasse, EC ;
Korneluk, RG ;
Kerbel, RS ;
Rosen, KV .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (45) :37383-37392
[62]   Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway [J].
Lo, HW ;
Hsu, SC ;
Ali-Seyed, M ;
Gunduz, M ;
Xia, WY ;
Wei, YK ;
Bartholomeusz, G ;
Shih, JY ;
Hung, MC .
CANCER CELL, 2005, 7 (06) :575-589
[63]   Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2 [J].
Longva, KE ;
Pedersen, NM ;
Haslekås, C ;
Stang, E ;
Madshus, IH .
INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) :359-367
[64]   A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study [J].
Macdonald, JS ;
McCoy, S ;
Whitehead, RP ;
Iqbal, S ;
Wade, JL ;
Giguere, JK ;
Abbruzzese, JL .
INVESTIGATIONAL NEW DRUGS, 2005, 23 (05) :485-487
[65]   The emerging role of lysophosphatidic acid in cancer [J].
Mills, GB ;
Moolenaar, WH .
NATURE REVIEWS CANCER, 2003, 3 (08) :582-591
[66]  
Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845
[67]   EFFECT OF EPIDERMAL GROWTH-FACTOR ON CU, ZN-SUPEROXIDE DISMUTASE EXPRESSION IN CULTURED FIBROBLASTS FROM RAT SKIN [J].
NISHIGUCHI, K ;
KIYOHARA, Y ;
KOMADA, F ;
IWAKAWA, S ;
OKUMURA, K .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1244-1249
[68]   The ErbB receptors and their ligands in cancer: An overview [J].
Normanno, N ;
Bianco, C ;
Strizzi, L ;
Mancino, M ;
Maiello, MR ;
De Luca, A ;
Caponigro, F ;
Salomon, DS .
CURRENT DRUG TARGETS, 2005, 6 (03) :243-257
[69]   The ErbB signaling network: receptor heterodimerization in development and cancer [J].
Olayioye, MA ;
Neve, RM ;
Lane, HA ;
Hynes, NE .
EMBO JOURNAL, 2000, 19 (13) :3159-3167
[70]   ErbB receptor-induced activation of Stat transcription factors is mediated by Src tyrosine kinases [J].
Olayioye, MA ;
Beuvink, I ;
Horsch, K ;
Daly, JM ;
Hynes, NE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) :17209-17218